| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |